Search results
Results from the WOW.Com Content Network
ASD-002 - a child-specific (non-acidic, sustained-release) anti-hyper excitatory ester prodrug of the potassium channel modulator NSAID mefenamic acid (MFA, approved as Ponstel) [24] to prevent toddlers from becoming non-verbal (developmental language disorder, DLD) Bryostatin-1 (MW-904) – protein kinase C stimulant [25]
When treatment with DMARDs fails, cyclophosphamide or steroid pulse therapy is often used to stabilise uncontrolled autoimmune disease. Some severe autoimmune diseases are being treated with bone marrow transplants in clinical trials , usually after cyclophosphamide therapy has failed.
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
The use of technology has begun to be implemented in ABA therapy for the treatment of autism. [49] Robots, gamification, image processing, story boards, augmented reality, and web systems have been shown to be useful in the treatment of autism. [49] These technologies are used to teach children with autism skill acquisition. [49]
Conventional DMARDs are known to be the first-line treatment for rheumatoid arthritis. [9] Treatment can be a monotherapy or in combination with other anti-arthritic medications. Common DMARDs include oral methotrexate, leflunomide, or sulfasalazine. Conventional DMARDs have a slow onset of action and can take 2–3 months to exhibit effect. [9]
More than ten percent of people taking Anakinra have injection site reactions, headaches, and have increased cholesterol levels. [1] Recipients have eight percent more patients decrease white blood cells counts, two percent more patients decrease platelets counts, one percent more patients get severe infections (4.5% for patients with asthma compared to 0% placebo patients with asthma). [1]
A separate list for children up to 12 years of age, known as the WHO Model List of Essential Medicines for Children (EMLc), was created in 2007 and is in its 9th edition. [ 10 ] [ 21 ] [ 22 ] [ 23 ] It was created to make sure that the needs of children were systematically considered such as availability of proper formulations .
Clinical guidelines provide treatment recommendations dependent on the clinical characteristics. [24] The treatment of most types of juvenile arthritis include medications, physical therapy, splints and in severe cases surgery. [12] The type and intensity of the treatment is largely based upon the subtype and severity of damage of the disease. [6]